Table 2.

Univariate findings of control of acromegaly, according to selected factors.

Characteristics	Univariate analyses
	Effect sizea	95% CI		P
Sex
Female	0.40	0.37	0.43	<0.0001
Male	0.42	0.39	0.45	<0.0001
Age at pegvisomant start
<30	0.44	0.37	0.51	0.0848
30–39	0.49	0.45	0.54	0.8053
40–49	0.44	0.40	0.48	0.0060
50–59	0.37	0.33	0.41	<0.0001
60+	0.35	0.31	0.39	<0.0001
Body mass index (kg/m2)
<25	0.35	0.30	0.41	<0.0001
25–30	0.40	0.36	0.44	<0.0001
30+	0.52	0.48	0.56	0.3673
Elevated random GH
No	0.36	0.29	0.43	0.0001
Yes	0.44	0.41	0.47	<0.0001
IGF-1 value at baseline (µg/L)
<300	0.24	0.20	0.29	<0.0001
300–500	0.36	0.32	0.40	<0.0001
500–700	0.50	0.45	0.55	0.9205
700+	0.56	0.52	0.61	0.0068
Medications for acromegaly
Peg only	0.37	0.35	0.40	<0.0001
Peg/other (non-SSA)	0.48	0.42	0.54	0.5292
Peg/SSA	0.41	0.38	0.45	<0.0001
Peg/SSA/other	0.57	0.49	0.64	0.0756
Pegvisomant mean dose during study (mg)
<10	0.32	0.28	0.36	<0.0001
10–15	0.33	0.30	0.37	<0.0001
15–20	0.42	0.38	0.46	<0.0001
20+	0.56	0.52	0.59	0.0029

^aEffect size <0.50 indicates a favorable effect on acromegaly control.